ABT
NYSEABBOTT LABORATORIES
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$43.1B
2021
$43.7B
2022
$40.1B
2023
$42.0B
2024
$44.3B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$44.3B
Net Income$6.5B
Gross Profit—
Oper Income$8.1B
EPS (dil)$3.72
Rev/sh$25.45
FCF/sh$4.25
Book/sh$30.30
Gross M—
Oper M18.2%
Profit M14.7%
FCF M16.7%
ROE12.4%
ROA7.5%
ROIC10.3%
R&D/Rev6.6%
Rev Y/Y5.7%
Rev 3Y CAGR0.5%
EPS Y/Y-51.3%
EPS 3Y CAGR-1.6%
FCF 3Y CAGR-1.8%
Payout63%
Div/sh$2.40
Shs Chg Y/Y0%
Current Ratio1.58
Quick Ratio1.18
Debt/Eq0.30
Int Coverage16.3×
Net Debt$7.4B
Total Debt$16.0B
Cash & Eq$8.5B
Total Assets$86.7B
Oper CF$9.6B
Capex$2.2B
Free CF$7.4B
Buybacks$893.0M
Equity$52.8B
Liabilities—
Shs Outstand1.74B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $8.4B | $8.4B | $6.5B | $6.8B | $8.1B |
| Net Income | $7.1B | $6.9B | $5.7B | $13.4B | $6.5B |
| Diluted EPS | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 |
| Operating Cash Flow | $10.5B | $9.6B | $7.3B | $8.6B | $9.6B |
| Free Cash Flow | $8.6B | $7.8B | $5.1B | $6.4B | $7.4B |
COMMUNITY · $ABT0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.